
This study aimed to identify clinically relevant markers for the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing the risk of heart failure (HF) events. The study conducted a meta-analysis of 13 randomized placebo-controlled trials involving 90,413 participants. It found that SGLT2 inhibitors significantly reduced the risk of HF hospitalization or cardiovascular death. In analysis, the study discovered that the improvement in chronic estimated glomerular filtration rate (eGFR) slope, which indicates kidney function stabilization, was significantly associated with the efficacy of SGLT2 inhibitors in reducing HF risk. This suggests that the cardiorenal axis plays a role in the beneficial effects of SGLT2 inhibitors on HF, and chronic eGFR slope can serve as a surrogate marker for their effectiveness.
Like
Save
Share